Navigation Links
YM BioSciences to raise approximately US$15 million
Date:3/5/2010

MISSISSAUGA, ON, March 5 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that it is raising approximately US$15 million in a "registered direct" offering of units at a price of US$1.20 per unit. Each unit consists of one common share and one half of one common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of US$1.60 commencing six months from closing for a period of five years from closing. Roth Capital Partners, LLC, served as lead placement agent. Bloom Burton & Co. Inc., Griffin Securities, Inc. and Haywood Securities Inc. served as co-placement agents for the transaction.

The funds will be used principally to fund YM's drug development activities and for general corporate purposes.

The transaction is expected to close on or about March 10, 2010, pending stock exchange approval.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the common shares in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About YM BioSciences

YM BioSciences Inc. is a life sciences product development. Together with the products from YM Australia (formerly Cytopia Limited), the Company is currently developing four late-stage products: nimotuzumab, an EGFR-targeting Affinity-Optimized Antibody(TM); CYT 387, a JAK 1/2 small molecule inhibitor, CYT 997, a potent, vascular disrupting agent and AeroLEF(R), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. YM has proven regulatory and clinical trial expertise and a diversified business model designed to reduce risk while advancing clinical products toward international approval, marketing and commercialization.

Nimotuzumab is a humanized monoclonal antibody in development worldwide, targeting multiple tumor types primarily in combination with radiation and chemoradiation. It is importantly differentiated from all other currently marketed EGFR-targeting agents due to its remarkably benign side-effect profile. Nimotuzumab's anti-tumor activity has led to its approval for marketing in 23 countries. In more than 9,000 patients reported as having been treated with nimotuzumab worldwide to date, Grade IV incidents of radiation dermatitis and incidents of severe rash have been only rarely observed and reports of the other severe side-effects that are typical of EGFR-targeting molecules have been equally rare. Nimotuzumab is licensed to YM's majority-owned, Canadian subsidiary, CIMYM BioSciences Inc., by CIMAB S.A., and was developed at the Center of Molecular Immunology. The products discovered by YM's recently acquired Australian subsidiary, YM Australia (formerly Cytopia Limited), include the JAK 1/2 inhibitor CYT387, and the novel VDA molecule CYT997. Both were discovered internally at Cytopia based on research led by Dr Andrew Wilks who identified the JAK 1/2 kinase enzymes. Both products are currently in clinical development. YM is developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE YM BioSciences Inc.

Back to top
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. TEI Biosciences PriMatrix(TM) Awarded Seal of Approval by American Podiatric Medical Association
3. YM BioSciences presents CYT387 and CYT997 data at international cancer conference
4. YM BioSciences granted two US patents for AeroLEF(R)
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. YM BioSciences reports second quarter 2010 operational and financial results
7. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
8. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
9. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
10. Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
11. YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... Oxitec CEO Hadyn Parry will testify ... before the United States House Committee on Science, Space and ... controlling the spread of the Aedes aegypti mosquito, ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has pioneered ... in Brazil , Panama ...
(Date:5/22/2016)... , ... May 22, 2016 , ... Doctors in Rome ... combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article on ... the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more than ...
(Date:5/20/2016)... ... 20, 2016 , ... The recent recall by Costco and Trader Joes of ... on May 12, 2016(1), demonstrates the need for faster and more cost effective bio-threat ... PathSensors, Inc. , PathSensor’s latest solution uses a biosensor technology called ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker ... as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than ... studies for preclinical and clinical safety programs. “We’ve seen significant demand for, and ...
Breaking Biology Technology:
(Date:3/18/2016)... 18, 2016 --> ... ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance ... in the border security market and the continuing migration crisis ... Europe has led visiongain to publish this ... --> defence & security companies in the ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
(Date:3/10/2016)... 10, 2016 --> ... report "Identity and Access Management Market by Component (Provisioning, ... Governance), by Organization Size, by Deployment, by Vertical, and ... MarketsandMarkets, The market is estimated to grow from USD ... 2020, at a Compound Annual Growth Rate (CAGR) of ...
Breaking Biology News(10 mins):